Promex and Realeve Launch Breakthrough Pulsante™ Device for Advanced Pain Management

Promex has been recognised alongside its partner, Realeve, for developing an innovative solution in chronic pain management. The two companies received the 2025 MedTech Breakthrough Award for Best New Pain Management Technology Solution for Realeve’s Pulsante™ system.

Pulsante™ is the first externally powered, implantable neuromodulation system designed to treat central nervous system (CNS) disorders such as strokes and cluster headaches. The device has already been tested in over 700 patients and holds an FDA Breakthrough Device designation. One of its key advantages is its ability to bypass the blood-brain barrier, opening new possibilities for delivering therapeutics directly to the brain.

It is activated by the patient using a handheld external controller, the Pulsante RC-200. This wireless device powers the implant, allowing for non-invasive, drug-free treatment of neurological conditions from the comfort of the patient’s home. The system is also designed to support data collection for ongoing monitoring and evaluation of treatment outcomes.

Promex played a key role in the development of Pulsante by translating Realeve’s design into working components. The company manufactured the core of the device, its complex internal header assembly—enclosed in a sealed ceramic and titanium case.

This award underscores the potential of Pulsante to offer a more personalised, effective, and patient-friendly alternative to traditional therapies—reducing reliance on medication and improving overall quality of life.